PT  - JOURNAL ARTICLE
AU  - Lim, Joey Ming Er
AU  - Hang, Shou Kit
AU  - Hariharaputran, Smrithi
AU  - Chia, Adeline
AU  - Tan, Nicole
AU  - Lee, Eng Sing
AU  - Chng, Edwin
AU  - Lim, Poh Lian
AU  - Young, Barnaby
AU  - Lye, David Chien
AU  - Le Bert, Nina
AU  - Bertoletti, Antonio
AU  - Tan, Anthony T
TI  - Omicron reactive multi protein specific CD4 T cells defines cellular immune response induced by inactivated virus vaccines
AID  - 10.1101/2022.05.25.22275616
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.05.25.22275616
4099  - http://medrxiv.org/content/early/2022/05/27/2022.05.25.22275616.short
4100  - http://medrxiv.org/content/early/2022/05/27/2022.05.25.22275616.full
AB  - Unlike mRNA vaccines based only on the Spike protein, inactivated SARS-CoV-2 vaccines should induce a diversified T cell response recognizing distinct structural proteins. Here we performed a comparative analysis of SARS-CoV-2 specific T cells in healthy individuals following vaccination with inactivated SARS-CoV-2 or mRNA vaccines. Relative to Spike mRNA vaccination, inactivated vaccines elicited a lower magnitude of Spike-specific T cells, but the combined Membrane, Nucleoprotein and Spike-specific T cell response was quantitatively comparable to the sole Spike T cell response induced by mRNA vaccines, and they efficiently tolerate the mutations characterizing the Omicron lineage. However, this multi-protein specific T cell response was not mediated by a coordinated CD4 and CD8 T cell expansion but by selected priming of CD4 T cells. These findings can help in defining the role of CD4 and CD8 T cells in the efficacy of the different vaccines to control severe COVID-19 after Omicron infection.Competing Interest StatementA.T. Tan, N. Le Bert and A. Bertoletti reported a patent for a method to monitor SARS-CoV-2-specific T cells in biological samples pending. The other authors have declared that no conflict of interest exists.Funding StatementThis study is supported by the Singapore Ministry of Health National Medical Research Council under its COVID-19 Research Fund (COVID19RF3-0060, COVID19RF-001 and COVID19RF-008).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study design and protocol for the COVID-19 PROTECT study group were assessed by National Healthcare Group (NHG) Domain Specific Review Board (DSRB) and approved under study number 2012/00917.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript